The GALNT14/PHB2/IGF1R cascade modulated the growth, migration, and anticancer drug resistance of HCC cells, thereby opening the possibility of identifying new therapeutic targets against HCC. The gene discussed is IGF1R; the disease is hepatocellular carcinoma.